Finding the best dose of pyrotinib for first-line advanced HER2 breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be HER2-positive (a type that grows quickly but can be treated with targeted therapy).
- Your cancer has come back (recurrent) or spread to other parts of the body (metastatic) and cannot be surgically removed.
- You have not had any prior systemic cancer treatment for this stage of the disease (except possibly trastuzumab in early-stage treatment).
- Your overall health is good (ECOG score 0 or 1) and your organs work well, such as normal blood counts and heart function (LVEF ≥50% measured by echocardiogram).
- You are between 18 and 75 years old and willing to use effective birth control during the study if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
This study tests a targeted therapy called pyrotinib for people with advanced or metastatic HER2-positive breast cancer. It aims to see how well the drug works in a real-world setting, helping guide treatment for this specific type of cancer.
This trial studies a new pre-surgery (neoadjuvant) treatment for HER2-positive breast cancer. It aims to see whether adding Py to HP before surgery can improve how patients’ cancers respond.
This trial tests whether adding pyrotinib to trastuzumab after surgery can reduce breast cancer coming back in people with HER2-positive, early-stage breast cancer. It may help some patients by improving treatment effectiveness, but it also requires meeting specific heart, lab, and health criteria.
This trial tests a combination of two targeted therapies, Trastuzumab Deruxtecan (T-DXd) and Pyrotinib, as a first treatment for HER2-positive breast cancer that has spread or cannot be removed. It aims to see if this combination works better than standard treatments.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.